CA2439879C - C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses - Google Patents

C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses Download PDF

Info

Publication number
CA2439879C
CA2439879C CA002439879A CA2439879A CA2439879C CA 2439879 C CA2439879 C CA 2439879C CA 002439879 A CA002439879 A CA 002439879A CA 2439879 A CA2439879 A CA 2439879A CA 2439879 C CA2439879 C CA 2439879C
Authority
CA
Canada
Prior art keywords
compound
deoxy
composition
adenosine
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002439879A
Other languages
English (en)
French (fr)
Other versions
CA2439879A1 (en
Inventor
Erica Van Tilburg
Ad Ijzerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Universiteit Leiden
Original Assignee
Can Fite Biopharma Ltd
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd, Universiteit Leiden filed Critical Can Fite Biopharma Ltd
Publication of CA2439879A1 publication Critical patent/CA2439879A1/en
Application granted granted Critical
Publication of CA2439879C publication Critical patent/CA2439879C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002439879A 2001-03-03 2002-03-03 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses Expired - Fee Related CA2439879C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0105337.0 2001-03-03
GB0105337A GB2372742A (en) 2001-03-03 2001-03-03 C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
PCT/IL2002/000160 WO2002070532A2 (en) 2001-03-03 2002-03-03 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses

Publications (2)

Publication Number Publication Date
CA2439879A1 CA2439879A1 (en) 2002-09-12
CA2439879C true CA2439879C (en) 2009-09-15

Family

ID=9909952

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439879A Expired - Fee Related CA2439879C (en) 2001-03-03 2002-03-03 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses

Country Status (9)

Country Link
US (2) US7084127B2 (https=)
EP (1) EP1368365A2 (https=)
JP (2) JP4359676B2 (https=)
KR (1) KR100585894B1 (https=)
CN (1) CN1259332C (https=)
AU (1) AU2002234851A1 (https=)
CA (1) CA2439879C (https=)
GB (1) GB2372742A (https=)
WO (1) WO2002070532A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527502A (ja) * 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド A1アデノシン受容体の部分的および全アゴニスト
JP2005132767A (ja) * 2003-10-30 2005-05-26 Sumitomo Chemical Co Ltd プリン化合物の製造方法
CA2550299C (en) * 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US20080070860A1 (en) * 2005-02-04 2008-03-20 Uti Limited Partnership Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AU2009231978C1 (en) * 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
EP2331542B1 (en) * 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
SG182285A1 (en) 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
BR112014018413A8 (pt) 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
WO2014068589A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of (1-{9-[(4s, 2r, 3r, 5r)-3, 4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl)-6-aminopurin-2-yl} pyrazole-4-yl)-n-methylcarboxamide
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
EP3448015B1 (en) * 2016-04-22 2021-11-24 Kowa Company, Ltd. Image capturing device provided with multiplexer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US5998423A (en) * 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
WO2000072799A2 (en) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias

Also Published As

Publication number Publication date
AU2002234851A1 (en) 2002-09-19
US7084127B2 (en) 2006-08-01
JP4359676B2 (ja) 2009-11-04
WO2002070532A3 (en) 2002-11-28
CA2439879A1 (en) 2002-09-12
US7189706B2 (en) 2007-03-13
GB2372742A (en) 2002-09-04
KR20030089512A (ko) 2003-11-21
US20040127452A1 (en) 2004-07-01
CN1259332C (zh) 2006-06-14
EP1368365A2 (en) 2003-12-10
WO2002070532A2 (en) 2002-09-12
JP2009167170A (ja) 2009-07-30
JP2004522794A (ja) 2004-07-29
CN1537115A (zh) 2004-10-13
KR100585894B1 (ko) 2006-06-07
US20040132686A1 (en) 2004-07-08
GB0105337D0 (en) 2001-04-18

Similar Documents

Publication Publication Date Title
CA2439879C (en) C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
EP0708781A1 (en) A 3 adenosine receptor agonists
Siddiqi et al. Search for new purine-and ribose-modified adenosine analogs as selective agonists and antagonists at adenosine receptors
KR100789162B1 (ko) 2'-데옥시-l-뉴클레오사이드의 합성
Jacobson et al. Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors
MX2011006892A (es) Sintesis de nucleosidos de purina.
HUP0001107A2 (hu) Monociklusos L-nukleozidok, ezek analógjai és ezeket tartalmazó gyógyszerkészítmények
NO172543B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte purinarabinosider
CN113616659B (zh) 含有腺苷衍生物的药物组合物
WO2010068708A2 (en) 3'-azido purine nucleotide prodrugs for treatment of viral infections
WO1998001459A1 (en) Novel n-alkoxyadenine derivatives acting as cytokine inhibitors
GB2372741A (en) C2,8-Disubstituted adenosine derivatives and their different uses
WO1997033591A1 (en) A method of treating disorders related to cytokines in mammals
CA2465264C (en) Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines
Pejanović et al. Synthesis and biological evaluation of some novel 4′-Thio-l-ribonucleosides with modified nucleobase moieties
Tsoukala et al. Keto and exomethylene pyranonucleosides as antitumor agents
Drenichev et al. Purine nucleosides and analogues bearing chiral substituents: medicinal chemistry and therapeutic perspective
AU2002336668A1 (en) Synthesis of 2-aralkoxy adenosines and 2-alkoxyadenosines
Zhang et al. Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3′-azido-2′, 3′-dideoxypurine nucleosides
Sivets et al. Syntheses of Clofarabine and Related C2′-β-fluorinated Nucleoside Analogues
Mulamoottil et al. Recent Advances in Synthesis and Biological Activity of 4′‐Thionucleosides
Sivets et al. Journal of New Developments in Chemistry
Mimochodková Development of selective agonists of adenosine receptors optimization of the synthetic procedures to obtain 2-chloropurine and analogues
Konč Modified nucleosides derived from pyrimido [4, 5-b] indole
Cosyn Synthesis and biological evaluation of purine and pyrimidine based ligands for the A3 and P2Y2 purinergic receptors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed